Xuhong et al. reported for the first time that the tpCR rate of the P + EC-TH neoadjuvant regimen in operable or locally advanced HER2-positive breast cancer was 73.7% (95% CI 48.8–90.9), which was about twice as high as that of the EC-TH neoadjuvant regimen reported in other trials, and the AEs were tolerable. The gene discussed is ERBB2; the disease is breast cancer.